Trial Profile
Investigation of the effect of eribulin mesilate on epithelial-mesenchymal transition in tumors of patients with metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2020
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- Acronyms FAS-01
- 27 Jul 2020 Status changed from suspended to completed.
- 02 Aug 2016 New trial record